MedTrace Logo

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-01-14

No results posted yet for this study

Summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

YL217

Patients will be treated with YL217 intravenous(IV)infusion.

DRUG

YL217

Patients will be treated with YL217 intravenous(IV)infusion.

DRUG

YL217

Patients will be treated with YL217 intravenous(IV)infusion.

Sponsors & Collaborators

  • MediLink Therapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859762 on ClinicalTrials.gov